Beam Therapeutics Inc (BEAM)

$34.14 +1.66 (5.11%)
Market Cap 3.34B
Revenue (ttm) 139.74M
Net Income (ttm) -79.99M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -57.24%
Debt to Equity Ratio 0.09
Volume 3,509,400
Avg Vol 2,105,500
Day's Range N/A - N/A
Shares Out 102.88M
Stochastic %K 96%
Beta 2.25
Analysts Strong Sell
Price Target $50.19

Company Profile

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304,...

Industry: Biotechnology
Sector: Healthcare
Phone: 857 327 8775
Website: beamtx.com
Address:
238 Main Street, Cambridge, United States
PepCF
PepCF Jun. 18 at 11:36 AM
$WVE SELLING panic is losing steam. MACD triggered a buy signal on June 9th and RSI is officially out of extreme oversold territory. In derivatives, volume is heavily skewed toward bullish calls. Solid support at $5.00 - $5.40, with resistance sitting at $6.20 - $6.50. Catalysts coming soon. Today our competitor $BEAM got FDA clearance... We are next!
0 · Reply
Doozio
Doozio Jun. 17 at 9:20 PM
$BEAM don’t get it TWSTed. It was always ONTO 🐒🍌🧠⏰♾️
0 · Reply
NewEarth
NewEarth Jun. 15 at 4:34 PM
$BEAM $CRBU $NTLA $PRME $REGN
0 · Reply
NewEarth
NewEarth Jun. 15 at 2:27 PM
$BEAM $CRBU $NTLA $PRME $REGN
0 · Reply
NewEarth
NewEarth Jun. 15 at 11:42 AM
$BEAM $CRBU $NTLA $PRME $REGN
0 · Reply
NewEarth
NewEarth Jun. 15 at 11:41 AM
$BEAM $CRBU $NTLA $PRME $REGN
0 · Reply
NewEarth
NewEarth Jun. 14 at 10:28 PM
$BEAM $CRBU $NTLA $PRME $REGN
0 · Reply
NewEarth
NewEarth Jun. 14 at 2:12 PM
$NTLA $CRBU $PRME $BEAM $REGN lol follow the Noble prize winners … Good job Jenny
0 · Reply
chop14
chop14 Jun. 4 at 2:26 PM
$TNYA need to pass 0.85 $IPDN $MARA $BEAM
0 · Reply
ATTAB0Y
ATTAB0Y Jun. 2 at 7:04 PM
$PRME $BEAM $CRSP $NTLA https://www.axios.com/2026/06/02/fda-gene-therapy-guidance-biotech
1 · Reply
Latest News on BEAM
Beam Therapeutics announces U.S. FDA clearned IND application for BEAM-304

2026-06-18T11:05:09.000Z - 1 day ago

Beam Therapeutics announces U.S. FDA clearned IND application for BEAM-304

Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-304 for the Treatment of Phenylketonuria (PKU) by the United States (U.S.) Food and Drug Administration

Jun 18, 2026, 7:00 AM EDT - 1 day ago

Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-304 for the Treatment of Phenylketonuria (PKU) by the United States (U.S.) Food and Drug Administration

The Healthcare M&A Wave

Jun 17, 2026, 12:30 PM EDT - 2 days ago

The Healthcare M&A Wave

ABT ALNY AMGN AMRX ANTX AZN BDX

Beam Therapeutics Transcript: AGM 2026

Jun 3, 2026, 10:30 AM EDT - 16 days ago

Beam Therapeutics Transcript: AGM 2026

Beam Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2026

May 20, 2026, 10:30 AM EDT - 4 weeks ago

Beam Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2026

Beam Therapeutics presents Phase 1/2 data for BEAM-302

2026-05-18T20:35:07.000Z - 4 weeks ago

Beam Therapeutics presents Phase 1/2 data for BEAM-302

Beam Therapeutics Presents Recently Reported Topline Clinical Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the American Thoracic Society (ATS) 2026 International Conference

May 18, 2026, 4:00 PM EDT - 4 weeks ago

Beam Therapeutics Presents Recently Reported Topline Clinical Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the American Thoracic Society (ATS) 2026 International Conference

Beam Therapeutics Supports AlphaDetect to Accelerate Detection of Alpha-1

May 13, 2026, 11:49 AM EDT - 5 weeks ago

Beam Therapeutics Supports AlphaDetect to Accelerate Detection of Alpha-1

Beam Therapeutics to Present at 2026 RBC Capital Markets Global Healthcare Conference

May 13, 2026, 7:00 AM EDT - 5 weeks ago

Beam Therapeutics to Present at 2026 RBC Capital Markets Global Healthcare Conference

Beam Therapeutics price target lowered to $39 from $40 at Bernstein

2026-05-13T10:37:27.000Z - 5 weeks ago

Beam Therapeutics price target lowered to $39 from $40 at Bernstein

Beam Therapeutics to Present Updated Biomarker Data from Phase 1/2 BEACON Trial Further Underscoring Risto-cel's Ability to Restore Red Blood Cell Health and Function in Sickle Cell Disease at EHA2026

May 12, 2026, 9:30 AM EDT - 5 weeks ago

Beam Therapeutics to Present Updated Biomarker Data from Phase 1/2 BEACON Trial Further Underscoring Risto-cel's Ability to Restore Red Blood Cell Health and Function in Sickle Cell Disease at EHA2026

Beam Therapeutics reports Q1 EPS (91c), consensus ($1.01)

2026-05-07T13:39:55.000Z - 6 weeks ago

Beam Therapeutics reports Q1 EPS (91c), consensus ($1.01)

Beam Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates

May 7, 2026, 7:00 AM EDT - 6 weeks ago

Beam Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates

Beam Therapeutics Earnings release: Q1 2026

May 7, 2026, 7:00 AM EDT - 6 weeks ago

Beam Therapeutics Earnings release: Q1 2026

Beam Therapeutics Quarterly report: Q1 2026

May 7, 2026, 7:00 AM EDT - 6 weeks ago

Beam Therapeutics Quarterly report: Q1 2026

Beam Therapeutics rises 10.7%

2026-04-27T16:07:48.000Z - 7 weeks ago

Beam Therapeutics rises 10.7%

Beam Therapeutics rises 10.8%

2026-04-27T14:34:03.000Z - 7 weeks ago

Beam Therapeutics rises 10.8%

Beam Therapeutics Proxy statement: Proxy filing

Apr 17, 2026, 8:00 AM EDT - 2 months ago

Beam Therapeutics Proxy statement: Proxy filing

Beam Therapeutics Proxy statement: Proxy filing

Apr 17, 2026, 8:00 AM EDT - 2 months ago

Beam Therapeutics Proxy statement: Proxy filing

Beam Therapeutics’ risto-cel shows efficacy in Sickle Cell Disease trial

2026-04-01T21:20:15.000Z - 2 months ago

Beam Therapeutics’ risto-cel shows efficacy in Sickle Cell Disease trial

Beam Therapeutics Announces Publication of BEACON Phase 1/2 Data for risto-cel in Patients with Sickle Cell Disease (SCD) in The New England Journal of Medicine

Apr 1, 2026, 5:12 PM EDT - 2 months ago

Beam Therapeutics Announces Publication of BEACON Phase 1/2 Data for risto-cel in Patients with Sickle Cell Disease (SCD) in The New England Journal of Medicine

Beam Therapeutics price target raised to $68 from $64 at Citi

2026-03-26T10:25:10.000Z - 3 months ago

Beam Therapeutics price target raised to $68 from $64 at Citi

Clear Street sees buying opportunity for Beam Therapeutics after study update

2026-03-25T16:55:13.000Z - 3 months ago

Clear Street sees buying opportunity for Beam Therapeutics after study update

Beam Therapeutics Transcript: Study result

Mar 25, 2026, 8:00 AM EDT - 3 months ago

Beam Therapeutics Transcript: Study result

Beam Therapeutics Press release: Study result

Mar 25, 2026, 8:00 AM EDT - 3 months ago

Beam Therapeutics Press release: Study result

Beam Therapeutics Slides: Study result

Mar 25, 2026, 8:00 AM EDT - 3 months ago

Beam Therapeutics Slides: Study result

Beam Therapeutics announces safety, efficacy data from BEAM-302 trial

2026-03-25T11:27:05.000Z - 3 months ago

Beam Therapeutics announces safety, efficacy data from BEAM-302 trial

Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development

Mar 25, 2026, 7:00 AM EDT - 3 months ago

Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development

Beam Therapeutics price target raised to $26 from $22 at RBC Capital

2026-02-25T14:29:20.000Z - 4 months ago

Beam Therapeutics price target raised to $26 from $22 at RBC Capital

Beam Therapeutics price target raised to $65 from $57 at Wedbush

2026-02-25T13:38:56.000Z - 4 months ago

Beam Therapeutics price target raised to $65 from $57 at Wedbush

Beam Therapeutics price target raised to $75 from $74 at Canaccord

2026-02-25T11:54:44.000Z - 4 months ago

Beam Therapeutics price target raised to $75 from $74 at Canaccord

Beam Therapeutics price target raised to $47 from $45 at BofA

2026-02-24T16:35:13.000Z - 4 months ago

Beam Therapeutics price target raised to $47 from $45 at BofA

PFE

Beam Therapeutics Earnings Call Transcript: Q4 2025

Feb 24, 2026, 8:00 AM EST - 4 months ago

Beam Therapeutics Earnings Call Transcript: Q4 2025

Beam Therapeutics Annual report: Q4 2025

Feb 24, 2026, 8:00 AM EST - 4 months ago

Beam Therapeutics Annual report: Q4 2025

Beam Therapeutics Earnings release: Q4 2025

Feb 24, 2026, 8:00 AM EST - 4 months ago

Beam Therapeutics Earnings release: Q4 2025

Beam Therapeutics announces $500M financing facility

2026-02-24T12:36:56.000Z - 4 months ago

Beam Therapeutics announces $500M financing facility

Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU)

Feb 24, 2026, 7:01 AM EST - 4 months ago

Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU)

Beam Therapeutics Announces $500 Million Strategic Financing Facility with Sixth Street

Feb 24, 2026, 7:00 AM EST - 4 months ago

Beam Therapeutics Announces $500 Million Strategic Financing Facility with Sixth Street

Beam Therapeutics to Host Investor Webcast for Fourth Quarter and Year-End 2025 Financial Results and New Liver-targeted Genetic Disease Program

Feb 23, 2026, 4:00 PM EST - 4 months ago

Beam Therapeutics to Host Investor Webcast for Fourth Quarter and Year-End 2025 Financial Results and New Liver-targeted Genetic Disease Program

Beam Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 8:15 PM EST - 5 months ago

Beam Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Beam Therapeutics Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 8:15 PM EST - 5 months ago

Beam Therapeutics Slides: 44th Annual J.P. Morgan Healthcare Conference

Beam Therapeutics Sets Strategic Priorities for its Genetic Disease and Hematology Franchises to Drive Execution of Late-Stage Clinical Programs and Extends its Operating Runway through Commercial Transition

Jan 11, 2026, 5:00 PM EST - 5 months ago

Beam Therapeutics Sets Strategic Priorities for its Genetic Disease and Hematology Franchises to Drive Execution of Late-Stage Clinical Programs and Extends its Operating Runway through Commercial Transition

Beam Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference

Dec 18, 2025, 4:01 PM EST - 6 months ago

Beam Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference

Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel (risto-cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (SCD) at American Society of Hematology (ASH) Annual Meeting

Dec 6, 2025, 8:00 AM EST - 6 months ago

Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel (risto-cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (SCD) at American Society of Hematology (ASH) Annual Meeting

Beam Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Nov 19, 2025, 10:30 AM EST - 7 months ago

Beam Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Beam Therapeutics to Participate in 2025 Jefferies London Healthcare Conference

Nov 12, 2025, 7:00 AM EST - 7 months ago

Beam Therapeutics to Participate in 2025 Jefferies London Healthcare Conference

Beam Therapeutics Earnings release: Q3 2025

Nov 4, 2025, 4:00 PM EST - 8 months ago

Beam Therapeutics Earnings release: Q3 2025

Beam Therapeutics Quarterly report: Q3 2025

Nov 4, 2025, 4:00 PM EST - 8 months ago

Beam Therapeutics Quarterly report: Q3 2025

Beam Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates

Nov 4, 2025, 7:00 AM EST - 8 months ago

Beam Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates

Beam Therapeutics to Present Updated Data from BEACON Phase 1/2 Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting

Nov 3, 2025, 9:00 AM EST - 8 months ago

Beam Therapeutics to Present Updated Data from BEACON Phase 1/2 Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting

Beam Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 8, 2025, 10:30 AM EDT - 10 months ago

Beam Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Beam Therapeutics Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Sep 4, 2025, 1:30 PM EDT - 10 months ago

Beam Therapeutics Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Beam Therapeutics Transcript: Citi's Biopharma Back to School Conference

Sep 3, 2025, 4:00 PM EDT - 10 months ago

Beam Therapeutics Transcript: Citi's Biopharma Back to School Conference

Beam Therapeutics to Participate in Upcoming September 2025 Investor Conferences

Aug 25, 2025, 7:00 AM EDT - 10 months ago

Beam Therapeutics to Participate in Upcoming September 2025 Investor Conferences

Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease

Aug 14, 2025, 7:00 AM EDT - 11 months ago

Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease

Beam Therapeutics Reports Second Quarter 2025 Financial Results and Provides Update on BEAM-302 Development Progress in Alpha-1 Antitrypsin Deficiency (AATD)

Aug 5, 2025, 7:00 AM EDT - 11 months ago

Beam Therapeutics Reports Second Quarter 2025 Financial Results and Provides Update on BEAM-302 Development Progress in Alpha-1 Antitrypsin Deficiency (AATD)

Beam Therapeutics Earnings release: Q2 2025

Aug 5, 2025, 7:00 AM EDT - 11 months ago

Beam Therapeutics Earnings release: Q2 2025

Beam Therapeutics Quarterly report: Q2 2025

Aug 5, 2025, 7:00 AM EDT - 11 months ago

Beam Therapeutics Quarterly report: Q2 2025

Beam Therapeutics Transcript: The European Hematology Association Congress 2025

Jun 13, 2025, 4:00 PM EDT - 1 year ago

Beam Therapeutics Transcript: The European Hematology Association Congress 2025

Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress

Jun 13, 2025, 7:00 AM EDT - 1 year ago

Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress

Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease

Jun 3, 2025, 7:00 AM EDT - 1 year ago

Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease

Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

May 29, 2025, 4:01 PM EDT - 1 year ago

Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

Beam Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2025

May 20, 2025, 11:00 AM EDT - 1 year ago

Beam Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2025

Beam Therapeutics to Highlight New Data from BEAM-101 Program in Sickle Cell Disease at European Hematology Association (EHA) 2025 Congress

May 14, 2025, 9:30 AM EDT - 1 year ago

Beam Therapeutics to Highlight New Data from BEAM-101 Program in Sickle Cell Disease at European Hematology Association (EHA) 2025 Congress

Beam Therapeutics to Participate in 2025 RBC Capital Markets Global Healthcare Conference

May 13, 2025, 7:00 AM EDT - 1 year ago

Beam Therapeutics to Participate in 2025 RBC Capital Markets Global Healthcare Conference

Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

May 12, 2025, 4:01 PM EDT - 1 year ago

Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

Beam Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 6, 2025, 7:00 AM EDT - 1 year ago

Beam Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

Beam Therapeutics Quarterly report: Q1 2025

May 6, 2025, 7:00 AM EDT - 1 year ago

Beam Therapeutics Quarterly report: Q1 2025

Beam Therapeutics Earnings release: Q1 2025

May 6, 2025, 7:00 AM EDT - 1 year ago

Beam Therapeutics Earnings release: Q1 2025

Beam Therapeutics Proxy statement: Proxy Filing

Apr 18, 2025, 8:00 AM EDT - 1 year ago

Beam Therapeutics Proxy statement: Proxy Filing

Beam Therapeutics Proxy statement: Proxy Filing

Apr 18, 2025, 8:00 AM EDT - 1 year ago

Beam Therapeutics Proxy statement: Proxy Filing

Beam Therapeutics Presents Additional Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at 2025 Alpha-1 Foundation 7th Global Research Conference and 10th Patient Congress

Apr 5, 2025, 7:00 AM EDT - 1 year ago

Beam Therapeutics Presents Additional Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at 2025 Alpha-1 Foundation 7th Global Research Conference and 10th Patient Congress

Biotech stocks plunge as FDA's Peter Marks resigns over RFK Jr. dispute, Moderna and Beam Therapeutics hit hard

Mar 31, 2025, 2:25 PM EDT - 1 year ago

Biotech stocks plunge as FDA's Peter Marks resigns over RFK Jr. dispute, Moderna and Beam Therapeutics hit hard

MRNA

Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) by the United States (U.S.) Food and Drug Administration

Mar 27, 2025, 4:01 PM EDT - 1 year ago

Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) by the United States (U.S.) Food and Drug Administration

Beam Therapeutics Transcript: Barclays 27th Annual Global Healthcare Conference

Mar 11, 2025, 3:30 PM EDT - 1 year ago

Beam Therapeutics Transcript: Barclays 27th Annual Global Healthcare Conference

Beam Therapeutics Transcript: Leerink Global Healthcare Conference 2025

Mar 10, 2025, 1:40 PM EDT - 1 year ago

Beam Therapeutics Transcript: Leerink Global Healthcare Conference 2025

Beam Therapeutics Transcript: Study Update

Mar 10, 2025, 8:00 AM EDT - 1 year ago

Beam Therapeutics Transcript: Study Update

Beam Therapeutics Press release: Study Update

Mar 10, 2025, 8:00 AM EDT - 1 year ago

Beam Therapeutics Press release: Study Update

Beam Therapeutics Slides: Study Update

Mar 10, 2025, 8:00 AM EDT - 1 year ago

Beam Therapeutics Slides: Study Update

Beam Therapeutics Announces Pricing of Underwritten Offering

Mar 10, 2025, 6:01 AM EDT - 1 year ago

Beam Therapeutics Announces Pricing of Underwritten Offering

Beam Therapeutics Announces Positive Initial Data for BEAM-302 in the Phase 1/2 Trial in Alpha-1 Antitrypsin Deficiency (AATD), Demonstrating First Ever Clinical Genetic Correction of a Disease-causing Mutation

Mar 10, 2025, 6:00 AM EDT - 1 year ago

Beam Therapeutics Announces Positive Initial Data for BEAM-302 in the Phase 1/2 Trial in Alpha-1 Antitrypsin Deficiency (AATD), Demonstrating First Ever Clinical Genetic Correction of a Disease-causing Mutation

Beam Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 3, 2025, 1:50 PM EST - 1 year ago

Beam Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Beam Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Reiterates Anticipated Catalysts

Feb 25, 2025, 7:00 AM EST - 1 year ago

Beam Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Reiterates Anticipated Catalysts

Beam Therapeutics Annual report: Q4 2024

Feb 25, 2025, 7:00 AM EST - 1 year ago

Beam Therapeutics Annual report: Q4 2024

Beam Therapeutics Earnings release: Q4 2024

Feb 25, 2025, 7:00 AM EST - 1 year ago

Beam Therapeutics Earnings release: Q4 2024

Beam Therapeutics to Participate in Upcoming March 2025 Investor Conferences

Feb 24, 2025, 7:00 AM EST - 1 year ago

Beam Therapeutics to Participate in Upcoming March 2025 Investor Conferences

Beam Therapeutics Transcript: Guggenheim SMID Cap Biotech Conference

Feb 6, 2025, 2:30 PM EST - 1 year ago

Beam Therapeutics Transcript: Guggenheim SMID Cap Biotech Conference

Beam Therapeutics to Participate in Guggenheim SMID Cap Biotech Conference

Jan 30, 2025, 7:00 AM EST - 1 year ago

Beam Therapeutics to Participate in Guggenheim SMID Cap Biotech Conference

Beam Therapeutics to Encore Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at 2025 Tandem Meetings of ASTCT and CIBMTR

Jan 23, 2025, 7:00 AM EST - 1 year ago

Beam Therapeutics to Encore Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at 2025 Tandem Meetings of ASTCT and CIBMTR

Beam Therapeutics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 13, 2025, 4:30 PM EST - 1 year ago

Beam Therapeutics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Beam Therapeutics Announces Progress in Hematology and Genetic Disease Franchises and Outlines Key 2025 Anticipated Catalysts

Jan 13, 2025, 7:00 AM EST - 1 year ago

Beam Therapeutics Announces Progress in Hematology and Genetic Disease Franchises and Outlines Key 2025 Anticipated Catalysts

Beam Therapeutics Transcript: Status Update

Dec 8, 2024, 11:00 PM EST - 1 year ago

Beam Therapeutics Transcript: Status Update

Beam Therapeutics Press release: Status Update

Dec 8, 2024, 11:00 PM EST - 1 year ago

Beam Therapeutics Press release: Status Update

Beam Therapeutics Slides: Status Update

Dec 8, 2024, 11:00 PM EST - 1 year ago

Beam Therapeutics Slides: Status Update

Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology (ASH) Annual Meeting

Dec 8, 2024, 1:45 PM EST - 1 year ago

Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology (ASH) Annual Meeting

Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting

Dec 7, 2024, 11:30 AM EST - 1 year ago

Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting

Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer

Dec 6, 2024, 7:00 AM EST - 1 year ago

Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer

Beam Therapeutics Expands its Board of Directors with Appointment of Chirfi Guindo, Global Biopharma Strategy and Commercial Leader

Dec 4, 2024, 7:00 AM EST - 1 year ago

Beam Therapeutics Expands its Board of Directors with Appointment of Chirfi Guindo, Global Biopharma Strategy and Commercial Leader

Beam Therapeutics Transcript: Jefferies London Healthcare Conference 2024

Nov 19, 2024, 5:00 AM EST - 1 year ago

Beam Therapeutics Transcript: Jefferies London Healthcare Conference 2024

Beam Therapeutics to Participate in 2024 Jefferies London Healthcare Conference

Nov 12, 2024, 4:01 PM EST - 1 year ago

Beam Therapeutics to Participate in 2024 Jefferies London Healthcare Conference

Beam Therapeutics Earnings Call Transcript: Q3 2024

Nov 5, 2024, 8:30 AM EST - 1 year ago

Beam Therapeutics Earnings Call Transcript: Q3 2024

Beam Therapeutics Quarterly report: Q3 2024

Nov 5, 2024, 8:30 AM EST - 1 year ago

Beam Therapeutics Quarterly report: Q3 2024

Beam Therapeutics Earnings release: Q3 2024

Nov 5, 2024, 8:30 AM EST - 1 year ago

Beam Therapeutics Earnings release: Q3 2024

Beam Therapeutics Reports Third Quarter 2024 Financial Results and Progress Across Priority Programs

Nov 5, 2024, 6:30 AM EST - 1 year ago

Beam Therapeutics Reports Third Quarter 2024 Financial Results and Progress Across Priority Programs

Beam Therapeutics to Hold Conference Call to Discuss Third Quarter 2024 Financial Results and Abstracts Accepted for Presentation at ASH Annual Meeting

Oct 29, 2024, 6:30 AM EDT - 1 year ago

Beam Therapeutics to Hold Conference Call to Discuss Third Quarter 2024 Financial Results and Abstracts Accepted for Presentation at ASH Annual Meeting

Beam Therapeutics Quarterly report: Q2 2024

Aug 6, 2024, 7:00 AM EDT - 2 years ago

Beam Therapeutics Quarterly report: Q2 2024

Beam Therapeutics Earnings release: Q2 2024

Aug 6, 2024, 7:00 AM EDT - 2 years ago

Beam Therapeutics Earnings release: Q2 2024

Beam Therapeutics Reports Pipeline Updates and Second Quarter 2024 Financial Results

Aug 6, 2024, 6:30 AM EDT - 2 years ago

Beam Therapeutics Reports Pipeline Updates and Second Quarter 2024 Financial Results

Beam Therapeutics Announces Transition of Chief Financial Officer

Jul 15, 2024, 6:30 AM EDT - 2 years ago

Beam Therapeutics Announces Transition of Chief Financial Officer

Beam Therapeutics Announces First Patient Dosed in the Phase 1/2 Study of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD)

Jun 26, 2024, 6:30 AM EDT - 2 years ago

Beam Therapeutics Announces First Patient Dosed in the Phase 1/2 Study of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD)

Beam Therapeutics Reports Data Highlighting Optimized Manufacturing Process for BEAM-101, an Investigational Base Editing Therapeutic for Sickle Cell Disease

Jun 14, 2024, 3:00 AM EDT - 2 years ago

Beam Therapeutics Reports Data Highlighting Optimized Manufacturing Process for BEAM-101, an Investigational Base Editing Therapeutic for Sickle Cell Disease

Beam Therapeutics Transcript: Jefferies 2024 Global Healthcare Conference

Jun 6, 2024, 1:30 PM EDT - 2 years ago

Beam Therapeutics Transcript: Jefferies 2024 Global Healthcare Conference

Beam Therapeutics to Participate in Jefferies Global Healthcare Conference

May 30, 2024, 6:30 AM EDT - 2 years ago

Beam Therapeutics to Participate in Jefferies Global Healthcare Conference

PepCF
PepCF Jun. 18 at 11:36 AM
$WVE SELLING panic is losing steam. MACD triggered a buy signal on June 9th and RSI is officially out of extreme oversold territory. In derivatives, volume is heavily skewed toward bullish calls. Solid support at $5.00 - $5.40, with resistance sitting at $6.20 - $6.50. Catalysts coming soon. Today our competitor $BEAM got FDA clearance... We are next!
0 · Reply
Doozio
Doozio Jun. 17 at 9:20 PM
$BEAM don’t get it TWSTed. It was always ONTO 🐒🍌🧠⏰♾️
0 · Reply
NewEarth
NewEarth Jun. 15 at 4:34 PM
$BEAM $CRBU $NTLA $PRME $REGN
0 · Reply
NewEarth
NewEarth Jun. 15 at 2:27 PM
$BEAM $CRBU $NTLA $PRME $REGN
0 · Reply
NewEarth
NewEarth Jun. 15 at 11:42 AM
$BEAM $CRBU $NTLA $PRME $REGN
0 · Reply
NewEarth
NewEarth Jun. 15 at 11:41 AM
$BEAM $CRBU $NTLA $PRME $REGN
0 · Reply
NewEarth
NewEarth Jun. 14 at 10:28 PM
$BEAM $CRBU $NTLA $PRME $REGN
0 · Reply
NewEarth
NewEarth Jun. 14 at 2:12 PM
$NTLA $CRBU $PRME $BEAM $REGN lol follow the Noble prize winners … Good job Jenny
0 · Reply
chop14
chop14 Jun. 4 at 2:26 PM
$TNYA need to pass 0.85 $IPDN $MARA $BEAM
0 · Reply
ATTAB0Y
ATTAB0Y Jun. 2 at 7:04 PM
$PRME $BEAM $CRSP $NTLA https://www.axios.com/2026/06/02/fda-gene-therapy-guidance-biotech
1 · Reply
AStrokeOfLuck
AStrokeOfLuck Jun. 2 at 6:35 PM
$CRSP $NTLA $BEAM $XBI $RCKT
0 · Reply
jewell69
jewell69 Jun. 2 at 4:34 PM
did everybody notice that $XBI is -4.02% today 6/2/26 as of 12:32 pm EDT biotech. stocks I've done in the past but dont own now: $SRPT -7.84% $QURE -5.95% $BEAM -5.33% $NTLA -4.95%
2 · Reply
gpaisa
gpaisa May. 30 at 5:03 PM
$BEAM heavy heavy monthly accumulation while price is sideways, build em up, distribute them out.
0 · Reply
EingeLTrade
EingeLTrade May. 29 at 6:17 PM
Next week going to be fun for $BEAM longs!
1 · Reply
hick0ry2
hick0ry2 May. 29 at 4:36 PM
$BEAM
0 · Reply
Avocado_smash
Avocado_smash May. 29 at 1:27 PM
$BEAM Structure and Trend strength up>
0 · Reply
NewEarth
NewEarth May. 29 at 11:04 AM
$BEAM $EDIT $NTLA $PRME $REGN
1 · Reply
NewEarth
NewEarth May. 29 at 11:04 AM
$BEAM $JNJ $NTLA $PRME $REGN
0 · Reply
EingeLTrade
EingeLTrade May. 28 at 7:50 PM
$33 resistance area since 2024... Once it clears this resistance, expect a massive breakout. $BEAM
0 · Reply
ClaudeBallz
ClaudeBallz May. 28 at 7:09 PM
$BEAM break this 33 resistance and 40 will come fast as fuk!!!!!!
0 · Reply
sogenerous
sogenerous May. 28 at 4:54 PM
That viral post about VERV-102 creating some positive sentiment change in GE sector despite being old data $PRME $BEAM
0 · Reply
KHG1962
KHG1962 May. 27 at 8:25 PM
$BEAM I am trading the range around a core position. Writing puts, selling some shares after puts being assigned higher, repeat.
0 · Reply